3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Cholangiocarcinoma
5
Melanoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Cyclophosphamide
155
Rituximab
148
Etoposide
84
fludarabine phosphate
73
Peripheral Blood Stem Cell Transplantation
68
Mycophenolic Acid
63
Busulfan
62
Filgrastim
59
Melphalan
58
Tacrolimus
54
Whole-Body Irradiation
51
Cytarabine
46
fludarabine
45
Radiotherapy
43
Methotrexate
41
Granulocyte Colony-Stimulating Factor
41
Cyclosporine
41
Vincristine
35
Antilymphocyte Serum
35
Carmustine
33
Doxorubicin
29
Prednisone
26
Thiotepa
25
Bendamustine Hydrochloride
24
Methylprednisolone
22
Ifosfamide
22
Dexamethasone
22
thymoglobulin
21
sargramostim
20
plerixafor
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, Non-Hodgkin
×
regorafenib
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled